Lilly Endowment Inc, an insider of Eli Lilly and Co (LLY), sold 93,752,410 shares of the company's stock on November 4, 2025, at a price of $946.40 per share. The total value of this transaction reached $88,727.19 million.
Following this sale, Lilly Endowment Inc retains ownership of 93,752,410 shares in Eli Lilly. Insider transactions like this one are reported to the SEC, providing transparency regarding how company executives and board members manage their stock holdings. While large sales can attract attention, they do not inherently signal negative sentiment towards the company. Such decisions reflect various personal or financial strategies, including diversification or tax planning.
Eli Lilly, headquartered in Indianapolis, Indiana, operates in the pharmaceuticals industry and employs 47,000 full-time staff. The company's market capitalization stands at $886.2 billion, with a P/E ratio of 48.13 and an EPS of 20.45. Eli Lilly's upcoming earnings report is scheduled for August 4, 2026, with an estimated EPS of $7.70 and revenue expectations of $17.9 billion.
Investors often analyze patterns of insider activity across multiple transactions and insiders to gain a broader perspective, rather than focusing solely on individual trades.